Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 433 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage IV Prostate Cancer Clear all
Completed Not applicable Interventional Results available

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

NCT01992016
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Soft Tissue Metastases, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Ranolazine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005810
View directory record Official record
Conditions
Prostate Cancer
Interventions
filgrastim, carboplatin, docetaxel, estramustine phosphate sodium
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

NCT00726596
View directory record Official record
Conditions
Prostate Cancer
Interventions
hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
5
States / cities
Hamilton, New Jersey • Morristown, New Jersey • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Sep 5, 2026, 5:56 AM EDT
Terminated Phase 2 Interventional Results available

Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer

NCT00670046
View directory record Official record
Conditions
Prostate Cancer
Interventions
valproic acid, standard of care follow-up
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00015977
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA prostate cancer vaccine, recombinant interleukin-12
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 5, 2026, 5:56 AM EDT
Withdrawn Not applicable Interventional

Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer

NCT02169063
View directory record Official record
Conditions
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
carbon-11 acetate, fluorine F 18 sodium fluoride, positron emission tomography, laboratory biomarker analysis
Radiation · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Phase 2 Interventional

Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005820
View directory record Official record
Conditions
Prostate Cancer
Interventions
nitrocamptothecin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
50
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Phase 2 Interventional

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00040755
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
rebimastat, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Phase 1Phase 2 Interventional

Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer

NCT00653757
View directory record Official record
Conditions
Prostate Cancer
Interventions
goserelin acetate, leuprolide acetate, image-guided radiation therapy, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Phase 1 Interventional

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

NCT00101972
View directory record Official record
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Phase 2 Interventional

Cilengitide in Treating Patients With Metastatic Prostate Cancer

NCT00103337
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
cilengitide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Not applicable Interventional

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

NCT00002520
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Not applicable Interventional Results available

Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer

NCT02489357
View directory record Official record
Conditions
Stage IV Prostate Cancer
Interventions
Cryosurgery, Degarelix, Laboratory Biomarker Analysis, Pembrolizumab
Procedure · Drug · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Phase 3 Interventional

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

NCT00002881
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, goserelin acetate, leuprolide acetate, suramin, therapeutic hydrocortisone, orchiectomy
Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2010 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Phase 2 Interventional

Docetaxel in Treating Patients With Stage IV Prostate Cancer

NCT00003781
View directory record Official record
Conditions
Pain, Prostate Cancer
Interventions
docetaxel, pain therapy, quality-of-life assessment
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 5, 2026, 5:56 AM EDT
Recruiting Phase 2 Interventional

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

NCT07025369
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Pelvic Lymphadenectomy, Positron Emission Tomography, Relugolix
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 5, 2026, 5:56 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

NCT03582475
View directory record Official record
Conditions
Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Neuroendocrine Neoplasm, Prostate Small Cell Carcinoma, Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8, Stage III Prostate Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Ureter Small Cell Carcinoma, Urothelial Carcinoma
Interventions
Carboplatin, Cisplatin, Docetaxel, Etoposide, Pembrolizumab
Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 5, 2026, 5:56 AM EDT
Terminated Phase 2 Interventional Results available

Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

NCT00937768
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Not applicable Interventional

Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen

NCT01682941
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Arm I Soy Bread, Arm II Soy-Almond Bread
Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Kidney Cancer

NCT00096629
View directory record Official record
Conditions
Kidney Cancer
Interventions
human prostate-specific membrane antigen plasmid DNA vaccine, mouse prostate-specific membrane antigen plasmid DNA vaccine
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00460031
View directory record Official record
Conditions
Prostate Cancer
Interventions
ketoconazole, lenalidomide, therapeutic hydrocortisone
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
6
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 5, 2026, 5:56 AM EDT
Active, not recruiting Phase 2 Interventional

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

NCT02713269
View directory record Official record
Conditions
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Melanoma, Prostate Carcinoma Metastatic in the Bone, Sarcoma, Solid Neoplasm, Spinal Cord Compression, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Thyroid Gland Carcinoma
Interventions
Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Thermal Ablation Therapy
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 5, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer

NCT00814788
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide, Everolimus
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Sep 5, 2026, 5:56 AM EDT
Completed No phase listed Observational

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

NCT02228265
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis
Other · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2020 · Synced Sep 5, 2026, 5:56 AM EDT